• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[30例高钙血症患者的分析]

[Analysis of 30 patients with hypercalcemia].

作者信息

Kobayashi T, Baba M, Tanaka N, Takeda T, Shiba E, Takai S, Mori T

机构信息

Department of Surgery II, Osaka University Medicine School, Japan.

出版信息

Nihon Geka Gakkai Zasshi. 1993 Oct;94(10):1125-30.

PMID:7901747
Abstract

We have treated 30 patients with hypercalcemia from 1984 to 1991. Twenty four out of 30 patients were associated with primary hyperparathyroidism and the other six were associated with malignancy. Of 24 cases primary hyperparathyroidism, 15 were due to single parathyroid adenoma, five to MEN 1 and one to familial hyperparathyroidism. In the other three cases, it was difficult to identify the cause of the hyperparathyroidism. Following conclusions were obtained: 1. Hypercalcemia shows no specific and characteristic symptoms, so it is essential to keep hypercalcemia in mind in diagnosis of patients with vague or general complaints. Malignancy associated hypercalcemia shows high serum calcium level and PTH level. When considering malignancy, it is easy to diagnose that it might be the cause of hypercalcemia. 2. When serum PTH is over 2000pg/ml (high sensitivity PTH assay) in primary hyperparathyroidism, the probability of swelling of multiple parathyroid glands should be considered in evaluation of localization study and surgery. When serum PTH is high or swelling of multiple glands is found. It is essential to evaluate the possibility of MEN 1.

摘要

1984年至1991年期间,我们共治疗了30例高钙血症患者。30例患者中,24例与原发性甲状旁腺功能亢进有关,另外6例与恶性肿瘤有关。在24例原发性甲状旁腺功能亢进病例中,15例是由单个甲状旁腺腺瘤引起,5例是由多发性内分泌腺瘤病1型(MEN 1)引起,1例是由家族性甲状旁腺功能亢进引起。在另外3例中,很难确定甲状旁腺功能亢进的病因。得出以下结论:1. 高钙血症没有特异性和特征性症状,因此在诊断有模糊或一般主诉的患者时,必须考虑到高钙血症。与恶性肿瘤相关的高钙血症表现为血清钙水平和甲状旁腺激素(PTH)水平升高。在考虑恶性肿瘤时,很容易诊断其可能是高钙血症的病因。2. 在原发性甲状旁腺功能亢进中,当血清PTH超过2000pg/ml(高灵敏度PTH检测)时,在评估定位研究和手术时应考虑多个甲状旁腺肿大的可能性。当血清PTH升高或发现多个腺体肿大时,必须评估MEN 1的可能性。

相似文献

1
[Analysis of 30 patients with hypercalcemia].[30例高钙血症患者的分析]
Nihon Geka Gakkai Zasshi. 1993 Oct;94(10):1125-30.
2
Primary hyperparathyroidism in pediatric patients.小儿原发性甲状旁腺功能亢进症
Pediatrics. 2005 Apr;115(4):974-80. doi: 10.1542/peds.2004-0804.
3
Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: experience by a single surgical team in Japan.1型多发性内分泌腺瘤病患者的原发性甲状旁腺功能亢进症:日本一个外科团队的经验
Henry Ford Hosp Med J. 1992;40(3-4):191-4.
4
Immunoassays for parathyroid hormone 1-84 in the diagnosis of hyperparathyroidism.甲状旁腺激素1-84免疫测定法在甲状旁腺功能亢进症诊断中的应用
J Bone Miner Res. 1991 Oct;6 Suppl 2:S43-50; discussion S61. doi: 10.1002/jbmr.5650061412.
5
Differential diagnosis of hypercalcemia.高钙血症的鉴别诊断。
J Bone Miner Res. 1991 Oct;6 Suppl 2:S51-9; discussion S61. doi: 10.1002/jbmr.5650061413.
6
Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.帕米膦酸二钠用于原发性甲状旁腺功能亢进患者高钙血症的术前治疗。
Surgery. 1991 Sep;110(3):480-6.
7
An association between neonatal severe primary hyperparathyroidism and familial hypocalciuric hypercalcemia in three kindreds.三个家族中新生儿严重原发性甲状旁腺功能亢进与家族性低钙血症性高钙血症之间的关联。
N Engl J Med. 1982 Feb 4;306(5):257-64. doi: 10.1056/NEJM198202043060502.
8
[Surgical therapy concept in primary hyperparathyroidism].[原发性甲状旁腺功能亢进症的手术治疗理念]
Schweiz Med Wochenschr Suppl. 2000;116:62S-65S.
9
[The value of the parathyrin-related protein (PTH-RP) in the diagnosis of cancer-associated hypercalcemia].[甲状旁腺素相关蛋白(PTH-RP)在癌症相关性高钙血症诊断中的价值]
Med Clin (Barc). 1995 Oct 14;105(12):450-4.
10
[Primary hyperparathyroidism. An analysis of 152 patients with special references to acute life threatening complications (acute hyperparathyroidism)].[原发性甲状旁腺功能亢进症。对152例患者的分析,特别提及急性危及生命的并发症(急性甲状旁腺功能亢进症)]
Schweiz Med Wochenschr. 1976;106 Suppl 3:1-61.